Influencing factors of hepatitis B virus reactivation after chemotherapy in hepatitis B surface antigen negative patients with malignant carcinoma
YANG Yang1, WEI Yan2, JIANG Xuehua1, CHEN Jian2, CHEN Zhiyong1, and YANG Long1
1.Department of Infectious Diseases, 2. Department of Oncology, Shanghai Municipal Corps Hospital of Chinese People’s Armed Police Force, Shanghai 201103, China
Abstract：Objective To investigate the occurrence of the related risk factor hepatitis B virus (HBV) reactivation after chemotherapy in hepatitis B surface antigen (HBsAg) negative patients with malignant carcinoma. Methods A total of five hundred and seventy HBsAg-negative patients with malignant carcinoma who received chemotherapy were recruited during the period of 2006-01 to 2014-12 in Shanghai Corps Hospital of Chinese People’s Armed Police Force. The patients were divided into reactivation group (n=25) and inactivation (n=545) group according to whether the virus was reactivated after chemotherapy. The general information, chemotherapy regimen and index of laboratory examination in both groups were analyzed retrospectively,2 test and logistic regression analysis were performed on potential influencing factors for HBV reactivation. Results The univariate analysis indicated that gender, hepatitis B surface antibody status, e antibody status, core antibody status and whether or no application of immune suppression were statistically significantly different between the two groups. The multivariate non-conditioned logistic regression analysis of these five factors indicated that male (OR=7.700, P＜0.001), hepatitis B surface antibody negative (OR=0.056, P＜0.001), E antibody positive (OR=4.670, P＜0.01) and application of immune suppression (OR=7.978, P＜0.01) were independent risk factors for HBV reactivation after chemotherapy. Conclusions For male, surface antibody negative, core antibody positive and application of immune suppression of HBsAg negative patients with malignant carcinoma, chemotherapy should closely monitor HBV whether reactivation or take early antiviral treatment to prevent HBV reactivation.
Chen W C, Cheng J S, Chiang P H, et al. A comparison of entecavir and lamivudine for the prophylaxis of hepatitis B virus reactivation in solid tumor patients undergoing systemic cytotoxic chemotherapy [J]. PLoS One, 2015, 10(6): e0131545.
[2]
Ho E Y, Yau T, Rousseau F, et al. Preemptive adefovir versus lamivudine for prevention of hepatitis B reactivation in chronic hepatitis B patients undergoing chemotherapy [J]. Hepatol Int, 2015, 9(2): 224-230.
[3]
Tang W, Chen L, Zheng R, et al. Prophylactic effect of lamivudine for lhemotherapy-induced hepatitis B reactivation in breast cancer: a Meta-analysis [J]. PLoS One, 2015, 10(6): e0128673.
[4]
Liu J Y, Sheng Y J, Ding X C, et al. The efficacy of lamivudine prophylaxis against hepatitis B reactivation in breast cancer patients undergoing chemotherapy: a meta-analysis [J]. J Formos Med Assoc, 2015, 114(2):164-173.
[5]
Yang Y, Du Y, Luo WX, et al. Hepatitis B virus reactivation and hepatitis in gastrointestinal cancer patients after chemotherapy [J]. Cancer Chemother Pharmacol, 2015, 75(4): 783-790.
[6]
Totani H, Kusumoto S, Ishida T, et al. Reactivation of hepatitis B virus (HBV) infection in adult T-cell leukemia-lymphoma patients with resolved HBV infection following systemic chemotherapy[J]. Int J Hematol, 2015, 101(4): 398-404.
[7]
Chen K L, Chen J, Rao H L, et al. Hepatitis B virus reactivation and hepatitis in diffuse large B - cell lymphoma patients with resolved hepatitis B receiving rituximab-containing chemotherapy: risk factor and survival [J]. Chin J Cancer, 2015, 34(1): 18.
[8]
Law M F, Lai H K, Chan H N, et al. The impact of hepatitis B virus(HBV) infection on clinical outcomes of patients with diffuse large B-cell lymphoma[J]. Eur J Cancer Care(Engl), 2015, 24(1): 117-124.
Chen K L, Chen J, Rao H L, et al. Hepatitis B virus reactivation and hepatitis in diffuse large B-cell lymphoma patients with resolved hepatitis B receiving rituximab-containing chemotherapy: risk factors and survival [J]. Chin J Cancer, 2015, 34(5): 225-234.
[12]
Elbedewy T A, Elashtokhy H E, Rabee E S, et al. Prevalence and chemotherapy-induced reactivation of occult hepatitis B virus among hepatitis B surface antigen negative patients with diffuse large B-cell lymphoma: significance of hepatitis B core antibodies screening[J]. J Egypt Natl Canc Inst, 2015, 27(1): 11-18.
2016, Vol. 27 
